Effect of Etanercept on the Success of Assisted Reproductive Technology in Patients with Endometrioma

Göğşen Önalan, Yusuf Aytaç Tohma, Hulusi Bülent Zeyneloğlu
Gynecologic and obstetric investigation · 2017 · vol. 83(4) , pp. 358–364 · doi:10.1159/000484895 · PMID:29208847 · W2769941475
article OA: closed CC0 ⤵ 24 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study found that etanercept treatment in patients with endometrioma undergoing assisted reproductive technology was associated with a significantly higher clinical pregnancy rate, though live birth rates did not reach statistical significance.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Aims: To determine the effects of a tumor necrosis factor inhibitor (etanercept) on pregnancy outcomes in patients with endometrioma who were treated with assisted reproductive technology. Methods: Sixty-eight infertile patients who had endometrioma were included in our retrospective case-control study. We administered etanercept (Enbrel, 50 mg in 1 mL intramuscularly) to 19 patients on the second day of their previous menstrual cycle. All patients were treated with assisted reproductive technology. Pregnancy and live birth rates (LBR) were documented. Results: When all other parameters (age, body mass index, infertility) are supposed to be constant, the clinical pregnancy rate was significantly higher in patients who used etanercept in an antagonist protocol than in patients who did not use etanercept (χ2 = 5.547; p = 0.019) but LBR did not reach a statistical significance (χ2 = 3.179; p = 0.075). The use of etanercept had an OR of 4.17 (95% CI 1.23–14.14) compared with not using etanercept for clinical pregnancy rate. The use of etanercept increased the rate of pregnancy (χ2 = 6.55; p = 0.01). The pregnancy rate with the use of etanercept had an OR of 4.23 (95% CI 1.35–13.25) compared with patients who did not use etanercept. In the same way, the use of etanercept increased LBR twofold, but it is not significant in the border line (χ2 = 3.771; p = 0.052). Conclusions: Etanercept may be a new non-hormonal therapy that may be an adjunct to treatment of infertile women with endometrioma. However, the safety of etanercept on embryos and fetuses has not been fully clarified.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriomainfertility

MeSH descriptors

Anti-Inflammatory Agents, Non-Steroidal Endometriosis Etanercept Infertility, Female Reproductive Techniques, Assisted Adult Anti-Inflammatory Agents, Non-Steroidal Case-Control Studies Endometriosis Endometriosis Etanercept Female Humans Infertility, Female Infertility, Female Live Birth Pregnancy Pregnancy Rate Reproductive Techniques, Assisted Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (29)

Cited by (24)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:20:07.505861+00:00
License: CC0 · commercial use OK